Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1397-1404

  Larson, David A ^a   Prados, Michael ^a   Lamborn, Kathleen R ^a   Smith, Vernon ^a   Sneed, Penny K ^a   Chang, Susan ^a   Nicholas, Kelly M ^a   Wara, William M ^a   Devriendt, Daniel ^a   Kunwar, Sandeep ^a   Berger, Mitch ^a   McDermott, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain neoplasm; Gamma Knife; Malignant glioma; Marimastat; Radiosurgery

Indexed keywords

DOSIMETRY; RADIOTHERAPY; SURGERY; TUMORS;

RADIOSURGERY;

ONCOLOGY;

MARIMASTAT;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GLIOMA; HUMAN; MALE; METASTASIS; MUSCULOSKELETAL DISEASE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SURVIVAL TIME; TUMOR GROWTH; VOMITING;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; HYDROXAMIC ACIDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOSURGERY; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 2242458568     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03743-4     Document Type: Article

References (27)

1. Wallner K.E., Galicich J.H., Krol G., et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 16:1989;1405-1409.
2. Liang B.C., Thornton A.F. Jr, Sandler H.M., et al. Malignant astrocytomas Focal tumor recurrence after focal external beam radiation therapy . J Neurosurg. 75:1991;559-563.
3. Gaspar L.E., Fisher B.J., Macdonald D.R., et al. Supratentorial malignant glioma Patterns of recurrence and implications for external beam local treatment . Int J Radiat Oncol Biol Phys. 24:1992;55-57.
4. Agbi C.B., Bernstein M., Laperriere N., et al. Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys. 23:1992;321-326.
5. Sneed P.K., Gutin P.H., Larson D.A., et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys. 29:1994;719-727.
6. Schupak K., Malkin M., Anderson L., et al. The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys. 32:1995;1167-1176.
7. Oppitz U., Maessen D., Zunterer H., et al. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol. 53:1999;53-57.
8. Lee S.W., Fraass B.A., Marsh L.H., et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas A quantitative dosimetric study . Int J Radiat Oncol Biol Phys. 43:1999;79-88.
9. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Nat Cancer Inst. 93:2001;178-193.
10. Yip D., Ahmad A., Karapetis C.S., et al. Matrix metalloproteinase inhibitors Applications in oncology . Invest New Drugs. 17:1999;387-399.
11. Tonn J.C., Kerkau S., Hanke A., et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer. 80:1999;764-772.
12. Heath E.I., Grochow L.B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 59:2000;1043-1055.
13. Rosemurgy A., Buckels J., Charnley R. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non resectable pancreatic cancer. [Abstract] Proc ASCO. 18:1999;261.
14. Nelson A.R., Fingleton B., Rothenberg M.L., et al. Matrix metalloproteinase Biologic activity and clinical implications . J Clin Oncol. 18:2000;1135-1149.
15. Fielding J., Scholefield J., Stuart P., et al. A randomized double-blind placebo controlled study of marimastat in patients with inoperable gastric adenocarcinoma. [Abstract] Proc ASCO. 19:2000;240.
16. 60Co gamma unit. Acta Oncol. 30:1991;363-367.
17. Levin V.A., Crafts D.C., Norman D.M., et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 47:1977;329-335.
18. Barker F.G., Chang S.M., Pounds T.R., et al. 18-Fluorodeoxyglucose uptake and survival in patients with suspected recurrent malignant glioma. Cancer. 79:1997;115-126.
19. Graves E.E., Nelson S.J., Vigneron D.B., et al. A preliminary study of the prognostic value of H-spectroscopy in Gamma Knife radiosurgery of recurrent malignant gliomas. Neurosurgery. 46:2000;319-328.
20. Hall W.A., Djalilian H.R., Sperduto P.W., et al. Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol. 13:1995;1642-1648.
21. Shrieve D.C., Alexander E. III, Wen P.Y., et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 36:1995;275-282.
22. Kondziolka D., Flickinger J.C., Bissonette D.J., et al. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurg. 41:1997;776-783.
23. Larson D.A., Gutin P.H., McDermott M., et al. Gamma knife for glioma Selection factors and survival . Int J Radiat Oncol Biol Phys. 36:1996;1045-1053.
24. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition A review of anti-tumour activity . Ann Oncol. 6:1995;967-974.
25. Millar A.W., Brown P.D., Moore J., et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol. 45:1998;21-26.
26. Wojtowicz-Praga S., Torri J., Johnson M., et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 16:1998;2150-2156.
27. Tierney G.M., Griffin N.R., Stuart R.C., et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer. 35:1999;563-568.